Trial Profile
A study to compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2020
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 21 Sep 2017 New trial record
- 24 Aug 2017 Results published in the AIDS.